Shenzhen Lachesis Mhealth builds “smart” wards for hospitals using digital devices and sensors to monitor and implement aspects of care such as infusions. The company serves over 700 clients in China, including top-tier hospitals like Peking Union Medical College Hospital and Peking University People’s Hospital. It plans to use new funding to advance research and development of smart medical products and to pursue medical big data and smart diagnosis ventures. Financially, Lachesis recently completed a Series B+ and previously closed a USD 29M Series B in August 2018. The firm positioned this Series B+ as the first financing deal in the Chinese medtech sector this year. Market context from the article notes Boston Consulting Group’s projection that the Chinese medtech market will grow to USD 55 billion by 2020.

Total raised

$22M

Funding rounds

1

Latest round

Series B

Latest activity

Jan 2020